Overview

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

Status:
Completed

Trial end date:
2003-11-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to assess the safety of CC-1088 to patients with myelodysplastic syndromes (MDS).

Phase:

Phase 2

Details

Lead Sponsor:

Celgene
Celgene Corporation